Goldman Sachs analyst Madhu Kumar maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price target from $64 to $18.
Why INVO Bioscience Shares Are Trading Higher By Over 31%; Here Are 20 Stocks Moving Premarket
INVO Bioscience, Inc. (NASDAQ: INVO) shares surged in pre-market trading after the company posted a narrower loss for the third quarter.